Market Intelligence, Neurotrophin Signaling Analysis, and High-Purity Reagents for Neurodegeneration & Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NGFRAP1/BEX3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | NGFRAP1 (BEX3) Recombinant Protein; High purity (>95%), Endotoxin <1EU/µg, Sequence Verified, Theoretical MW 14.5 kDa. E. coli or HEK293 expressed. | View NGFRAP1 Products |
| PPI Partner | NGFR/p75NTR Intracellular Domain; For binding validation and competition assays. Sequence Verified. | View NGFR Products |
| Gene Delivery | NGFRAP1 Promise-ORF / Lentivirus; Full-length ORF for stable cell lines and localization studies. | View NGFRAP1 Products |
| Benchmark Ab | Anti-NGFRAP1 (BEX3) Recombinant Antibody; High-specificity tool for Co-IP, ICC, and target engagement. Sequence Verified. | View NGFRAP1 Products |
| Validator | NGFRAP1 siRNA Set; For knockdown verification and specificity controls. | View NGFRAP1 Products |
| Related Target: TRAF6 | Downstream signaling partner (NF-κB pathway activation) | View TRAF6 Products |
| Related Target: BEX1 | Brain Expressed X-linked family member (functional paralog) | View BEX1 Products |
| Related Target: XIAP | Apoptosis inhibitor often counter-regulated by BEX3 networks. | View XIAP Products |
| Related Target: MAGEA3 | Cancer/testis antigen interacting with BEX3; relevant for melanoma drug resistance. | View MAGEA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PPI Interface Stability (NGFR-NGFRAP1) | High-purity recombinant proteins with native folding verified by CD spectroscopy; available as untagged or GST/His fusions for flexible assay design. |
| Cross-species Translation (Rodent/Cyno) | Human/Mouse/Rat/Cyno ortholog proteins available with >95% sequence homology; critical for in vivo neurodegeneration models. |
| Cell-Based Apoptosis Validation | Lentivirus-mediated stable expression ensuring native intracellular localization and processing; matched siRNA controls for specificity. |
| Selectivity/Specificity Control | Homolog panel (BEX1, BEX2, BEX4) proteins strictly verified by mass spec for counter-screening; validated siRNA and scramble controls. |
| False Positive Binding in Cell Lysates | NGFRAP1-specific siRNA included for rescue/specificity checks in Co-IP. |
Live NGFRAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NGFRAP1 (BEX3, NADE) therapeutics is intensifying as the scientific community recognizes its pivotal role as an intracellular adaptor protein of the p75 neurotrophin receptor (NGFR) mediating apoptosis and cell cycle arrest. Unlike direct NGF/NGFR blockade, targeting the intracellular NGFRAP1 interaction offers pathway-specific modulation without disrupting trophic support. The current landscape is dominated by academic and preclinical efforts exploring small-molecule disruption of the BEX3-p75NTR interaction, PROTACs for targeted degradation, and gene-therapy vectors designed to modulate BEX3 tumor-suppressive signaling. As first-generation small molecule inhibitors of the NGFR-NGFRAP1 interface enter preclinical development, the next wave of R&D is targeting allosteric modulators, peptide-based disruptors, and emerging PROTAC technologies for neurodegenerative diseases and high-risk solid tumors (e.g., glioblastoma, neuroblastoma, and melanoma). The field is shifting from extracellular receptor modulation toward intracellular protein-protein interface (PPI) targeting, with NGFRAP1/BEX3 emerging as a model system for next-generation assay development.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / Peptide PPI Disruptors | Academic consortia, Neurodegeneration biotechs | Alzheimer's, Parkinson's, ALS, Glioblastoma | High-affinity screening using SPR/BLI with high-purity recombinant NGFRAP1 and NGFR ICD proteins; pH-dependent binding panels. |
| Targeted Protein Degradation (PROTAC / Molecular Glue) | Early Preclinical Innovators | Glioblastoma, Ovarian Cancer, Solid Tumors | Degradation kinetics assays using sequence-verified lentivirus cell lines and recombinant BEX3 domains as bait. |
| Gene Therapy & RNA-based Therapeutics (siRNA/ASO) | Neurology-focused biotechs, Oncology gene therapy platforms | CNS Trauma, Alzheimer's, Melanoma, Breast Cancer | Specificity validation using validated siRNA sets for knockdown controls; lentivirus stable cell line construction for apoptosis quantification. |